Damora Therapeutics, Inc. reported $8.2M of revenue over the trailing twelve months, +1541% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $8.2M (to Q2 2026). Net income: −$263M, trailing twelve months to Q2 2026. Operating margin: −7382%, trailing twelve months to Q2 2026. EPS: $7.49, trailing twelve months to Q2 2026.

DMRADamora Therapeutics, Inc.

Healthcare

$21.12+636% 1Y

$21.12

$3.0052 weeks$34.14

DMRA as reported

Damora Therapeutics, Inc. reported $8.2M of revenue over the trailing twelve months, +1541% on the year before. 8 reported series are charted on this page, each one as filed.

$8.2M

Revenue, trailing twelve months · to Q2 2026 · +1541% against the twelve months before

Net income: −$263M
Net income · +1484% year on year · trailing twelve months to Q2 2026
Operating margin: −7382%
Operating margin · trailing twelve months to Q2 2026
EPS: $7.49
EPS · −157% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for DMRA, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$8.2M	+1541%	Q2 2026
Net income	−$263M	+1484%	Q2 2026
EPS	$7.49	−157%	Q2 2026
Operating margin	−7382%	n/a	Q2 2026
Net margin	−7297%	n/a	Q2 2026
ROE	−96%	n/a	Q2 2026
ROA	−80%	n/a	Q2 2026
Free cash flow	−$43M	n/a	Q4 2022 · 14 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.